Bladder cancer: bladder preservation, a recognized curative option for selected patients

A first international guideline

On 16 September 2026, the American Society for Radiation Oncology (ASTRO) published its first guideline devoted to radiation therapy for bladder cancer. It appeared in the journal Practical Radiation Oncology. It was developed with the American Society of Clinical Oncology (ASCO) and the European Society for Radiotherapy and Oncology (ESTRO), and endorsed by the European Association of Urology (EAU).

Its central message matters: for carefully selected patients, bladder preservation is no longer only a fallback for those who cannot undergo surgery. It is a curative option in its own right, to be presented alongside bladder removal.

Trimodal therapy, in three steps

The recommended bladder-preserving treatment combines three steps, hence the name “trimodal”: first, the most complete possible resection of the tumor through the natural passages, that is through the urethra, without incision; then, radiation therapy to the bladder; at the same time as radiation, a systemic treatment, usually chemotherapy, which makes cancer cells more sensitive to radiation.

The goal is the same as with surgery: to cure the cancer, while keeping a functioning bladder.

Who can be considered for this option?

The guideline concerns so-called “muscle-invasive” cancers: the tumor has invaded the muscle of the bladder wall, but has not spread to lymph nodes or other organs. In staging terms, this corresponds to stages cT2 to cT4a, N0, M0.

Certain features make a patient a better candidate: a single tumor smaller than 7 centimeters, a cancer that is mainly urothelial carcinoma, the most common form of bladder cancer, no extensive carcinoma in situ, that is flat cancer cells lining the bladder, and no hydronephrosis, a swollen kidney because urine no longer drains normally.

For patients at higher risk of spread, the guideline also recommends systemic therapy before trimodal therapy. The decision is always made in a multidisciplinary meeting, with the urologist, the radiation oncologist and the medical oncologist.

What does this guideline really change?

Previously, bladder preservation was mainly offered to patients too frail to undergo removal. From now on, it can be discussed even with patients who could have surgery, after a multidisciplinary evaluation.

Long-term follow-up studies suggest that, in well-selected patients, cancer outcomes are comparable to those of bladder removal. Caution is still needed: these comparisons rely largely on observational studies, and equivalence has not been shown for all patients. That is precisely why selection is so strict.

After treatment: close follow-up

Keeping the bladder requires rigorous follow-up: a cystoscopy, an examination of the bladder with a small camera passed through the urethra, after treatment to check the response, then regular surveillance, because a cancer can come back in the preserved bladder.

If the cancer comes back despite treatment, removing the bladder remains possible as a salvage option. The guideline also notes that radiation therapy can be useful after removal, when the risk of local recurrence is high, for example if the cancer had grown beyond the bladder, reached lymph nodes, or if surgical margins were positive. Having a neobladder, a new bladder rebuilt from intestine, does not rule it out.

Key takeaways

This international guideline alone decides nothing for a given patient: every case is different. Above all, it confirms that today, for certain muscle-invasive bladder cancers, there is a curative alternative to removal, to be discussed with your urologist and in a multidisciplinary meeting.

If you are affected by bladder cancer, do not hesitate to ask whether a multidisciplinary evaluation, with a urologist, a radiation oncologist and a medical oncologist, is possible before deciding, and what follow-up would be planned if the bladder is preserved.

This article is for information only; it does not replace your doctor's advice.